Kantar Health Blog

  • Neesha Suvarna
    Oncology Conference Insight: AACR - Final progression-free survival (PFS) data from the PALOMA-1 phase II trial was presented at the Plenary Session of the 2014 American Association for Cancer Research (AACR; Finn, abstract CT-101). Observers were expecting positive news, since interim analyses already had shown PFS benefit for palbociclib (PD 0332991, Pfizer/Amgen/Onyx) and Pfizer had indicated via press release that the final PFS results were positive (February 3, 2014).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GU --- Prostate cancer is the most common cancer in men and the second most common cause of cancer deaths in men in the United States. The incident population of prostate cancer in the United States was above 200,000 patients in 2013. The rate of prostate cancer growth varies from very slow to moderately rapid, and some patients may have prolonged survival even after the cancer has metastasized to distant sites such as bone.
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    Oncology Conference Insight: ASCO GI 2014 --- Hepatocellular carcinoma (HCC) is a particularly challenging disease. Surgery remains the only curative strategy for patients with HCC, however not all patients are eligible for surgery. The approval of Nexavar® (sorafenib, Bayer/Onyx/Amgen) revolutionized HCC, providing a targeted therapy option for patients with HCC and an advance over de facto standard doxorubicin. The enthusiasm for Nexavar is dampened by the fact that not all patients may be eligible for Nexavar treatment due to poor liver function, and options remain limited for patients whose disease progresses.
    Continue Reading > | Go comment! | Share
  • I-SPY 2 Graduates its First Experimental Regimen

    by Stephanie Hawthorne | Dec 13, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- The I-SPY 2 trial is an innovative “find a winner” trial that aims to address some of these challenges by screening a number of different novel experimental agents in the neoadjuvant setting in combination with a standard chemotherapy regimen of paclitaxel followed by AC compared to standard chemotherapy alone. In this novel trial design, the randomization of patients to treatment arms is adaptive, with randomization probabilities continuing to be updated as the trial progressed.
    Continue Reading > | Go comment! | Share
  • Anastrozole: a new option for breast cancer chemoprevention?

    by Stephanie Hawthorne | Dec 13, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- There are a variety of known risk factors for developing breast cancer, such as obesity, nulliparity, and age at time of menarche and menopause. For patients with a particularly high risk of developing breast cancer, including those who have a family history of the disease or have tested positive for deleterious BRCA1 or BRCA2 mutations, there are several options available for risk reduction. Currently, two hormonal agents, tamoxifen and raloxifene, are FDA approved to reduce the risk of breast cancer in patients at high risk of developing the disease.
    Continue Reading > | Go comment! | Share